logo-loader

Squarex looks to raise $20 mln to develop its drug to prevent cold sores

Published: 16:17 10 Jan 2019 EST

Squarex CEO Hugh McTavish joined Proactive Investors at the 11th Annual BioTech Showcase in San Francisco.

Squarex is a clinical stage pharmaceutical company developing a topical formulation to prevent recurrent cold sores and other infections caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2.

Ramp Metals Launches Drilling Program in Pursuit of High-Grade Nickel in...

Ramp Metals CEO Jordan Black joined Steve Darling from Proactive to introduce the company to the public domain and share exciting developments in the mining industry. With a background as a geotechnical engineer and experience in venture capital, including a notable role in taking GoldSpot...

47 minutes ago